Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.

NCT01394796 is registered in ClinicalTrials.gov with Parc de Salut Mar as lead sponsor.

NCT NCT01394796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01394796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.
Lead sponsor
Parc de Salut Mar
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2010
Completion date
February 28, 2011
Enrollment
31 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

down syndrome